3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Lymphoma
3
Neuroblastoma
2
Myelodysplastic Syndromes
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Influenza, Human
2
Skin Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Older Patients
1
Multiple Myeloma
1
Metabolic Diseases
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Immunologic Deficiency Syndromes
1
Hodgkin Disease
1
Hepatoblastoma
1
Ganglioneuroblastoma
1
Interventions
Magnetic Resonance Spectroscopy
7
Cyclophosphamide
7
dinutuximab
6
Topotecan
5
Isotretinoin
5
Doxorubicin
5
Biopsy
5
sargramostim
4
Vincristine
4
Stem Cell Transplantation
4
Specimen Handling
4
Radiation
4
Platinum
4
Melphalan
4
Colony-Stimulating Factors
4
Cisplatin
4
Carboplatin
4
1,2-diaminocyclohexaneplatinum II citrate
4
Thiotepa
3
Temozolomide
3
Irinotecan
3
Etoposide
3
Congresses as Topic
3
3-Iodobenzylguanidine
3
etoposide phosphate
2
Razoxane
2
Dexrazoxane
2
Busulfan
2
lorlatinib
1
iberdomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ganglioneuroblastoma
×
Influenza Vaccines
×
1 year
×
Clear all
NCT07502287
2026-03-30
DUAL-NK-NB
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled